IXICO PLC (AIM:IXI, FRA:PYPB, OTC:PHYOF) (LON:IXI) CFO Grant Nash joins Proactive London's Katie Pilbeam about returning to double-digit revenue growth again in 2022 as the impact of Covid-19 on drug trials eases and activity picks up again.
Nash explains that having enjoyed exceptional growth over recent years, industry-wide impacts of COVID-19 and the unexpected developments from their largest client's trials have had an impact but the market itself has not changed.
As a result, Ixico now expects to report revenues of £8.7mln in the year to end September 2021 and underlying profits [EBITDA] of £1.2mln compared to revenues of £9.5mln and underlying profits of £1.3mln in 2020.